The FDA has approved two new indications for trastuzumab deruxtecan (T-DXd; Enhertu, AstraZeneca/Daiichi Sankyo), broadening the drug’s use for patients with HER2-positive early breast cancer and moving the therapy into potentially curative treatment settings.  The expanded indications for the anti-HER2 antibody-drug conjugate cover both the neoadjuvant and adjuvant settings. …
Source

0 Comments

Leave a reply

©2026 Game Changers ®

Terms and Conditions | Disclaimer

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Welcome

Install
×
PWA Add to Home Icon

Install this Game Changers on your iPhone PWA Add to Home Banner and then Add to Home Screen

×
x

Add Game Changers to your Homescreen by tap on share icon.

or

Log in with your credentials

or    

Forgot your details?

or

Create Account

Enable Notifications OK No thanks